Akebia Therapeutics, Inc. NASDAQ:AKBA

Akebia Therapeutics stock price today

$3.06
+1.11
+56.92%
Financial Health
0
1
2
3
4
5
6
7
8
9

Akebia Therapeutics stock price monthly change

+54.76%
month

Akebia Therapeutics stock price quarterly change

+54.76%
quarter

Akebia Therapeutics stock price yearly change

+62.50%
year

Akebia Therapeutics key metrics

Market Cap
394.90M
Enterprise value
123.79M
P/E
-1.35
EV/Sales
0.42
EV/EBITDA
-3.15
Price/Sales
0.40
Price/Book
12.76
PEG ratio
-0.01
EPS
-0.22
Revenue
187.22M
EBITDA
-6.88M
Income
-43.03M
Revenue Q/Q
-18.74%
Revenue Y/Y
-30.92%
Profit margin
-31.63%
Oper. margin
-24.13%
Gross margin
68.9%
EBIT margin
-24.13%
EBITDA margin
-3.68%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Akebia Therapeutics stock price history

Akebia Therapeutics stock forecast

Akebia Therapeutics financial statements

Akebia Therapeutics, Inc. (NASDAQ:AKBA): Profit margin
Jun 2023 56.37M -11.17M -19.82%
Sep 2023 42.04M -14.48M -34.46%
Dec 2023 56.19M 614K 1.09%
Mar 2024 32.60M -17.98M -55.16%
Akebia Therapeutics, Inc. (NASDAQ:AKBA): Analyst Estimates
Mar 2024 32.60M -17.98M -55.16%
Sep 2025 47.33M -7.41M -15.67%
Oct 2025 47.28M -8.19M -17.34%
Dec 2025 51.78M -7.17M -13.85%
  • Analysts Price target

  • Financials & Ratios estimates

Akebia Therapeutics, Inc. (NASDAQ:AKBA): Debt to assets
Jun 2023 253712000 280.51M 110.57%
Sep 2023 234998000 274.42M 116.78%
Dec 2023 241703000 272.28M 112.65%
Mar 2024 225477000 252.73M 112.09%
Akebia Therapeutics, Inc. (NASDAQ:AKBA): Cash Flow
Jun 2023 3.62M 0 -8M
Sep 2023 -7.16M 0 50K
Dec 2023 -2.30M 0 -1.29M
Mar 2024 -19.43M 0 18.47M

Akebia Therapeutics alternative data

Akebia Therapeutics, Inc. (NASDAQ:AKBA): Employee count
Aug 2023 204
Sep 2023 204
Oct 2023 204
Nov 2023 204
Dec 2023 204
Jan 2024 204
Feb 2024 204
Mar 2024 167
Apr 2024 167
May 2024 167
Jun 2024 167
Jul 2024 167

Akebia Therapeutics other data

25.28% -6.84%
of AKBA is owned by hedge funds
48.12M -9.55M
shares is hold by hedge funds

Akebia Therapeutics, Inc. (NASDAQ:AKBA): Insider trades (number of shares)
Period Buy Sel
Feb 2024 0 203429
May 2024 0 46856
Transaction Date Insider Security Shares Price per share Total value Source
Sale
HADAS NICOLE R. officer: SVP, Chief Legal Officer
Common Stock 12,016 $1.26 $15,140
Sale
DAHAN MICHEL officer: SVP, Chi.. Common Stock 34,840 $1.26 $43,898
Sale
DAHAN MICHEL officer: SVP, Chi.. Common Stock 8,661 $1.58 $13,684
Sale
HADAS NICOLE R. officer: SVP, Chief Legal Officer
Common Stock 5,974 $1.58 $9,439
Sale
BUTLER JOHN P. director, officer: CEO and Pres..
Common Stock 46,570 $1.58 $73,581
Sale
BURKE STEVEN KEITH officer: SVP, Chi.. Common Stock 7,169 $1.58 $11,327
Sale
HADAS NICOLE R. officer: SVP, Chief Legal Officer
Common Stock 7,411 $1.52 $11,265
Sale
DAHAN MICHEL officer: SVP, Chi.. Common Stock 10,744 $1.52 $16,331
Sale
BURKE STEVEN KEITH officer: SVP, Chi.. Common Stock 8,367 $1.52 $12,718
Sale
BUTLER JOHN P. director, officer: CEO and Pres..
Common Stock 37,733 $1.52 $57,354
Patent
Grant
Filling date: 31 Mar 2016 Issue date: 10 May 2022
Grant
Filling date: 6 Jul 2020 Issue date: 8 Mar 2022
Application
Filling date: 15 Jun 2021 Issue date: 10 Feb 2022
Application
Filling date: 2 Oct 2019 Issue date: 2 Dec 2021
Grant
Filling date: 10 Feb 2020 Issue date: 20 Jul 2021
Application
Filling date: 12 Nov 2020 Issue date: 8 Jul 2021
Application
Filling date: 22 Jun 2020 Issue date: 13 May 2021
Application
Filling date: 6 Jul 2020 Issue date: 29 Apr 2021
Application
Filling date: 8 May 2019 Issue date: 11 Mar 2021
Application
Filling date: 10 Feb 2020 Issue date: 5 Nov 2020
Wednesday, 18 December 2024
prnewswire.com
Thursday, 5 December 2024
zacks.com
Tuesday, 3 December 2024
prnewswire.com
prnewswire.com
Wednesday, 27 November 2024
zacks.com
Monday, 25 November 2024
prnewswire.com
Friday, 22 November 2024
zacks.com
Wednesday, 20 November 2024
seekingalpha.com
Thursday, 14 November 2024
prnewswire.com
Tuesday, 12 November 2024
prnewswire.com
Thursday, 7 November 2024
seekingalpha.com
zacks.com
prnewswire.com
Friday, 1 November 2024
prnewswire.com
prnewswire.com
Tuesday, 22 October 2024
prnewswire.com
Tuesday, 15 October 2024
prnewswire.com
Thursday, 10 October 2024
prnewswire.com
Monday, 7 October 2024
prnewswire.com
Tuesday, 1 October 2024
prnewswire.com
Thursday, 5 September 2024
prnewswire.com
Tuesday, 3 September 2024
prnewswire.com
Monday, 26 August 2024
zacks.com
prnewswire.com
Friday, 16 August 2024
zacks.com
Saturday, 10 August 2024
seekingalpha.com
Thursday, 8 August 2024
zacks.com
prnewswire.com
Friday, 2 August 2024
prnewswire.com
Thursday, 1 August 2024
prnewswire.com
  • What's the price of Akebia Therapeutics stock today?

    One share of Akebia Therapeutics stock can currently be purchased for approximately $3.06.

  • When is Akebia Therapeutics's next earnings date?

    Unfortunately, Akebia Therapeutics's (AKBA) next earnings date is currently unknown.

  • Does Akebia Therapeutics pay dividends?

    No, Akebia Therapeutics does not pay dividends.

  • How much money does Akebia Therapeutics make?

    Akebia Therapeutics has a market capitalization of 394.90M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 33.49% to 194.62M US dollars.

  • What is Akebia Therapeutics's stock symbol?

    Akebia Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "AKBA".

  • What is Akebia Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Akebia Therapeutics?

    Shares of Akebia Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Akebia Therapeutics's key executives?

    Akebia Therapeutics's management team includes the following people:

    • Mr. John P. Butler MBA Chief Executive Officer, Pres & Director(age: 61, pay: $1,200,000)
    • Dr. Steven Keith Burke Senior Vice President of R&D and Chief Medical Officer(age: 64, pay: $681,870)
    • Mr. Dell Faulkingham Senior Vice President & Chief Commercial Officer(age: 52, pay: $660,040)
    • Mr. Michel Dahan Senior Vice President & Chief Operating Officer(age: 46, pay: $655,140)
    • Mr. David A. Spellman Senior Vice President, Chief Financial Officer & Treasurer(age: 48, pay: $591,060)
    • Mr. Jason A. Amello Executive Officer(age: 57, pay: $435,660)
  • How many employees does Akebia Therapeutics have?

    As Jul 2024, Akebia Therapeutics employs 167 workers.

  • When Akebia Therapeutics went public?

    Akebia Therapeutics, Inc. is publicly traded company for more then 11 years since IPO on 20 Mar 2014.

  • What is Akebia Therapeutics's official website?

    The official website for Akebia Therapeutics is akebia.com.

  • Where are Akebia Therapeutics's headquarters?

    Akebia Therapeutics is headquartered at 245 First Street, Cambridge, MA.

  • How can i contact Akebia Therapeutics?

    Akebia Therapeutics's mailing address is 245 First Street, Cambridge, MA and company can be reached via phone at +61 78712098.

Akebia Therapeutics company profile:

Akebia Therapeutics, Inc.

akebia.com
Exchange:

NASDAQ

Full time employees:

167

Industry:

Biotechnology

Sector:

Healthcare

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

245 First Street
Cambridge, MA 02142

CIK: 0001517022
ISIN: US00972D1054
CUSIP: 00972D105